## Addax

ADDAX Biosciences is a spin-off of the University of Turin born in 2017 after a long research activity on pathological tissue fixation. It aims to eradicate Formalin – a carcinogenic substance – from hospitals, research centres and laboratories, and replace it with a non-toxic fixative.







## **GAF®**

Formaldehyde is a carcinogenic, mutagenic and neurotoxic substance banned in Europe (EU Dir. 895/2014). In lack of a valid and safe alternative, formalin (water solution based on formaldehyde) is still widely used in hospitals as a histological fixative. Addax has developed and patented GAF® (Glyoxal Acid Free), an innovative product that provides comparable or better fixation efficiency over the entire

range of Formalin applications, but is non-carcinogenic. GAF® provides diagnosis accuracy without exposing healthcare professionals to the risk of developing work-related diseases and cancers. GAF® is a patented, CE-marked, and FDA-approved product that has undergone several independent, national, and international validation trials which demonstrate its diagnostic value.